new cdc guidelines should boost revenue, page-5

The only problem with Biota is the pipeline, if they want to become a serious player on the Nasdaq they'll have to bulk up the pipe especially in the discovery and pre-clinical compounds... funny enough they have an excellent mid-late stage pipe which could place it in tier 2 biotech land ($2-$5bn USD cap). Significant revenues from LANI and Relenza could eventually set the stage to a tier 1 biotech but that's many years away.

The best thing they can do with the funds now is to re-invest in early stage compounds, purchase a platform based technology, expand the existing platform etc. A dividend is nice and should be maintained to some degree if possible... but bulking up the pipe significantly and listing on the Nasdaq will sure raise some eyebrows from US analysts.

This is Biota's chance to move up the ranks and join the likes of Human Genome Sciences, Onyx Pharmaceuticals Inc and Dendreon Corp.